Jump to content

Stocks more likely to make profit in footsie 100


Recommended Posts

So far I have not heard any one for Stocks more likely to rise in value and make profit in 2018.

My own view is that Footsie won't go far this year. If not crash but stay 5% to 10% in the range ,what it is at the moment.

My own recommendation for this year for stocks is

1. Legal & General  

2. Sophos

3  GSK

Number 1 & 3 is also more for the Dividends And No 3 is more for the future danger of Cyber attacks

I would like to hear from others their views .

Peter77

Link to comment

Peter,

 

its good to hear some suggestions. For LGEN I note this has a yield of 5.3%, which seems reasonable. I looked at a FTSE 100 table and this yield makes LGEN the 12th highest paying FTSE100 stock, based on this value. Interestingly I hold Imperial Brands, which is the 11th highest payer at 5.4% and I too bought this for the yield alone, so in a sense we have both reached the same decision. With IMB I am expecting capital growth over the next 12 months because a) it is a defensive stock and b) the price has come down from a high of around £41.30 reached in 2017. I expect this correction to be reversed and IMB are investing in new products to protect their market share.

 

I don't however know much about Legal and General!

 

In respect of Sophos, this is not a FTSE100 constituent so not sure if that affects your decision making (it initially looked like you were trying to identify FTSE100 stocks to out perform the index?) I don't know much about it except the stock has roughly doubled over the last 12 months, so it would be a great feat if it were to do that again. (Do you know anything about the company its prospects or its products, btw?) it is on a very punchy rating of f/c PER 121 which is roughly akin to OCADO - a stock that is widely believed to be over-valued. I suppose largely it depends if SOPHOS can meet its profit targets for the year. This only pays 0.6% yield, so I would not be buying it for income, and for me the rating is too punchy to justify buying it now, without doing more research. Perhaps you can write up some notes?

 

In terms of GSK, I do partially resonate your thinking, and in a similar vein to LGEN, this could be a good buy for the yield of 6.1%, but perhaps with a bounce in the share price too. Perhaps there is M&A potential here?

I have held this share before, and given the three you picked then GSK would be my preference as the dividend yield is the highest of the three with some chance of share price growth too.

(note the cover is < 1 so is there a risk the dividend could be cut or frozen?)

 

You may want to plot these shares again the FTSE100 and see how they have tracked it, re-basing for say two years.  There is a good piece of work that could be undertaken here.

 

 

 

 

Link to comment

Archived

This topic is now archived and is closed to further replies.

  • image.png

  • Posts

    • Hi again, Finally is even IG Europe integrated with TradingView! Thank you @IG.  Is there any way to change between live and demo account?
    • His mention of C3.ai, with its focus on predictive maintenance and smart meter management, highlights how AI isn't just improving operational efficiency but also creating new growth opportunities. Anderson also points to Microsoft’s AI-enhanced cloud services as another example of AI setting the stage for future business models. For investors, it’s less about immediate profitability and more about the long-term potential of AI.
    • XRP supporters have noticed a significant shift in the cryptocurrency's price following the SEC’s recent legal actions. As the situation unfolds, understanding these dynamics is crucial for investors. SEC’s Appeal: A Shock to the Market On Thursday, the U.S. SEC announced its intention to appeal favorable rulings from the Ripple lawsuit that concluded a few months ago. By Friday, this intention became official as the SEC submitted applications to the U.S. appellate court. This news sent shockwaves through the XRP market, leading many investors to sell off their tokens, which caused the price to drop sharply. XRP’s Recent Price Movements Price Drop After the SEC Announcement On October 2, just before the SEC’s appeal news broke, XRP reached an intraday high of $0.6058. However, by October 3, the price plummeted to $0.5101, marking a 15.79% decrease. Interestingly, despite the SEC's appeal being registered on October 4, XRP showed signs of recovery.  As of writing this article XRP Price was trading at 0.54 With 1.375 increase in last 24 hours as per Coinpedia markets data For a more detailed analysis of XRP's potential price trajectory, be sure to check out our comprehensive XRP price prediction article. Comparing the 2020 Lawsuit Impact In December 2020, the situation was markedly different. When the SEC initially filed its lawsuit against Ripple, XRP's price dropped dramatically. On December 20, XRP was valued at $0.5678, but by December 23, following the lawsuit announcement, it had plummeted to $0.2214, a staggering 61% decline. The situation worsened as more exchanges began delisting XRP. By December 29, the price had fallen to $0.1748, nearly 70% lower than its pre-lawsuit price. Resilience and Future Predictions Despite the recent turmoil, XRP’s ability to recover has sparked optimism among its supporters. Some market analysts, including Bobby A, believe that the current legal developments may present a “sell trap.” He predicts XRP could reach $4.23 soon, emphasizing that macro charts remain bullish. Furthermore, there are suggestions that XRP could potentially rise to $6 in the near future. After hitting a low of $0.17 during the 2020 lawsuit, XRP surged by 1,021% to $1.96 by April 2021. If a similar rally occurs from the recent low of $0.5101, it could see prices climbing as high as $5.72, with the possibility of reaching $6 by January. As the SEC's legal actions continue to unfold, XRP's resilience offers hope for future price rallies. Investors are encouraged to stay informed about market developments.
×
×
  • Create New...
us